SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

UCB S.A. UCBJF OTC

Other OTC • Healthcare • Biotechnology • BE • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

UCB S.A. (UCBJF) is a Biotechnology company in the Healthcare sector, currently trading at $328.30. It has a SharesGrow Score of 79/100, indicating a strong investment profile with 6 out of 7 criteria passed.

Financials: revenue is $7.7B, +12.7%/yr average growth. Net income is $1.6B, growing at +79.6%/yr. Net profit margin is 20.1% (strong). Gross margin is 74.3% (+4.7 pp trend).

Balance sheet: total debt is $2.2B against $10.9B equity (Debt-to-Equity (D/E) ratio 0.21, conservative). Current ratio is 1.38 (adequate). Debt-to-assets is 12.4%. Total assets: $18.2B.

Analyst outlook: 2 / 2 analysts rate UCBJF as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 15/100 (Fail), Growth 90/100 (Pass), Past 100/100 (Pass), Health 83/100 (Pass), Moat 80/100 (Pass), Future 100/100 (Pass), Income 85/100 (Pass).

UCBJF SharesGrow Score Overview

79/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 15/100

Valuation — P/E, PEG, Forward PEG

GROWTH 90/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 83/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 80/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 85/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — UCBJF

UCBJF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

UCBJF: +12.7%/yr revenue is, +79.6%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

UCBJF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet UCBJF: Debt-to-Equity (D/E) ratio 0.21 (conservative), Current ratio is 1.38 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

UCBJF: Gross margin is 74.3% (+4.7 pp trend), $62B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 80/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 2 analysts rate UCBJF as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

UCBJF: Net profit margin is 20.1%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range150.7-345.39

Volume90

Avg Volume (30D)853

Market Cap$62.5B

Beta (1Y)0.23

Dividend Yield$1.5827

Share Statistics

EPS (TTM)8.20

Shares Outstanding$190M

IPO Date2008-08-26

Employees9,052

CEOJean-Christophe Tellier

Financial Highlights & Ratios

Revenue (TTM)$7.74B

Gross Profit$5.75B

EBITDA$2.01B

Net Income$1.56B

Operating Income$2.01B

Total Cash$2.47B

Total Debt$2.24B

Net Debt$-6M

Total Assets$18.15B

Price / Earnings (P/E)40

Price / Sales (P/S)8.08

Analyst Forecast

Rating ConsensusBuy

Analysts Covering2

Buy 100% Hold 0% Sell 0%

Company Info

CountryBE

ExchangeOther OTC

CurrencyUSD

ISINBE0003739530

Price Chart

UCBJF

UCB S.A. ↗ · Other OTC

Healthcare • Biotechnology

150.70 52WK RANGE 345.39

People Also View

Arcus Biosciences, Inc.

Ikena Oncology, Inc.

Foghorn Therapeutics Inc.

Verrica Pharmaceuticals Inc.

Acasti Pharma Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message